Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
1,791
datasets available to search
ShareScore release 0.9.0
Dataset results
1,791 results for “attention”
Figure 6 in Original specimens and type localities of early described polychaete species (Annelida) from Norway, with particular attention to species described by O.F. Müller and M. Sars
Figure 6. Localities for polychaetes described by Otto Friderich Müller, Michael Sars, Anders Ørsted, Heinrich Rathke and Gerhard Armauer Hansen from Norwegian waters. Upper left map inset shows stations sampled by the Norwegian North-Atlantic Expedition (NNHE) 1876–1878.
Figure 5 in Original specimens and type localities of early described polychaete species (Annelida) from Norway, with particular attention to species described by O.F. Müller and M. Sars
Figure 5. Original label written by Michael Sars for Ampharete finmarchica. Original text reads: 'Amphicteis finmarchica Sars. Ramfjorden Tromsö S.' Natural History Museum, Oslo.
Supplementary file 48 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 48: Proportion of patients on methylphenidate with agitation</p>
Supplementary file 51 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 51: Proportion of patients on methylphenidate with sleep disorder</p>
Supplementary file 47 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 47: Proportion of patients on methylphenidate with isolation</p>
Supplementary file ROBINS-I Risk of Bias table in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies.
<p>ROBINS-I Risk og Bias Table</p>
Supplementary file 19 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 19 Proportion of patients on methylphenidate with asthenia </p>
Supplementary file 13 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 13: Proportion of patients on methylphenidate with tachycardia </p>
Supplementary file 80 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 80: Proportion of participants on methylphenidate with rhinitis</p>
Supplementary file 77 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 77: Proportion of participants on methylphenidate with pharyngitis</p>
Supplementary file 75 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 75: Proportion of participants on methylphenidate with allergies</p>
Supplementary file 74 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 74: Proportion of participants on methylphenidate with pyrexia</p>
Supplementary file 70 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 70: Proportion of participants on methylphenidate with dyspepsia </p>
Supplementary file 79 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 79: Proportion of participants on methylphenidate with with rash</p>
Supplementary file 69 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 69: Proportion of participants on methylphenidate with vomiting </p>
Supplementary file 68 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 68: Proportion of participants on methylphenidate with upset stomach</p>
Supplementary file 83 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 83: Proportion of participants on methylphenidate with skin problems</p>
Supplementary file 76 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 76: Proportion of participants on methylphenidate with cold symptoms </p>
Supplementary file 62 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 62: Proportion of participants on methylphenidate with decreased appetite </p>
Supplementary file 60 in Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents - assessment of possible adverse events in non-randomised studies
<p>Supplementary file 60: Proportion of participants on methylphenidate with abdominal pain</p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.